Literature DB >> 18397685

Therapeutic drug monitoring of vancomycin in severe sepsis and septic shock.

M Vázquez1, P Fagiolino, A Boronat, M Buroni, C Maldonado.   

Abstract

BACKGROUND: The sudden changes (increase in capillary permeability, edema formation, vasodilation and hypotension) observed in septic patients and the measurements taken in order to revert this situation make vancomycin concentrations difficult to interpret. Therapeutic drug monitoring (TDM) of vancomycin is routinely performed at steady state, target concentrations are peaks between 20 and 40 mg/l and troughs of 5-10 mg/l. Lately, continuous infusion of vancomycin (CIV) has been used as an alternative mode of administration mainly in critically ill patients with sepsis or septic shock. Despite this novel mode of administration, the need of drug monitoring in this population is under discussion.
OBJECTIVE: The aim of our study was to test the usefulness of a multi-compartment model in order to understand the rapid changes that occur in critically ill patients.
MATERIALS AND METHODS: A prospective, cohort study was carried out in the intensive care unit of the University Hospital. 25 intensive care unit adults patients with severe sepsis or septic shock receiving vancomycin in CIV modality for documented gram-positive infections were included in the study. Once the infusion was started, blood samples were drawn periodically and analyzed by fluorescence polarisation immunoassay (FPIA, TDx, Abbott Laboratories, Chicago, IL, USA). A multi-compartment model was used to predict vancomycin level evolution throughout the treatment of patients with sepsis.
RESULTS: High doses of vancomycin were administered in order to rescue patients from septic shock. Plasma drug concentration dropped while clinical condition of patients worsened. Conversely, drug levels increased spontaneously once the infection was reverted. The theoretical model provided greater insight into pharmacokinetic features related with the use of vancomycin in septic patients.
CONCLUSIONS: There was consistency between the model based prediction and the experimental data so dose adjustment was performed in order to reach target concentrations above 20 mg/l and an initial dose of 3 grams of vancomycin per day was recommended to reach these levels.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18397685     DOI: 10.5414/cpp46140

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Ther        ISSN: 0946-1965            Impact factor:   1.366


  6 in total

1.  Appropriate antibiotic dosage levels in the treatment of severe sepsis and septic shock.

Authors:  Fabio Silvio Taccone; Maya Hites; Marjorie Beumier; Sabino Scolletta; Frédérique Jacobs
Journal:  Curr Infect Dis Rep       Date:  2011-10       Impact factor: 3.725

2.  Dose Rationale for Amoxicillin in Neonatal Sepsis When Referral Is Not Possible.

Authors:  Salvatore D'Agate; Flora Tshinanu Musuamba; Oscar Della Pasqua
Journal:  Front Pharmacol       Date:  2020-09-25       Impact factor: 5.810

Review 3.  Benefits of therapeutic drug monitoring of vancomycin: a systematic review and meta-analysis.

Authors:  Zhi-Kang Ye; Hui-Lin Tang; Suo-Di Zhai
Journal:  PLoS One       Date:  2013-10-18       Impact factor: 3.240

4.  Hyperammonemia associated with valproic acid concentrations.

Authors:  Marta Vázquez; Pietro Fagiolino; Cecilia Maldonado; Ismael Olmos; Manuel Ibarra; Silvana Alvariza; Natalia Guevara; Laura Magallanes; Ivette Olano
Journal:  Biomed Res Int       Date:  2014-04-29       Impact factor: 3.411

5.  The pharmacokinetics of vancomycin during the initial loading dose in patients with septic shock.

Authors:  Wasan Katip; Sutep Jaruratanasirikul; Sutthiporn Pattharachayakul; Wibul Wongpoowarak; Arnurai Jitsurong; Aroonrut Lucksiri
Journal:  Infect Drug Resist       Date:  2016-11-22       Impact factor: 4.003

6.  Describing vancomycin serum levels in pediatric intensive care unit (ICU) patients: are expected goals being met.

Authors:  Talita Muniz Maloni; Talita Rantin Belucci; Sandra Regina Malagutti; Guilherme Henrique Campos Furtado
Journal:  BMC Pediatr       Date:  2019-07-18       Impact factor: 2.125

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.